Results 41 to 50 of about 10,605 (184)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

Patient Preference and Adherence, 2020
Jason K Lee,1 Suvina Amin,2 Michelle Erdmann,3 Atif Kukaswadia,4 Jelena Ivanovic,5 Aren Fischer,4 Alain Gendron6 1Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator Inc.
Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gendron A   +6 more
doaj  

Allergen‐Functionalized Microfluidic Immunoadsorption Platform for Selective Depletion of Peanut‐Specific Antibodies From Whole Blood

Journal of Polymer Science, EarlyView.
We present a microfluidic immunoadsorption platform functionalized with a layer‐by‐layer (LbL) nanofilm composed of poly(diallyldimethylammonium chloride) (PDDA) and protein extract (PE) for selective capture of peanut‐specific antibodies directly from the whole blood obtained from a peanut allergy mouse model.
Hesaneh Ahmadi, Nur Hendri Wahyu Firdaus, Rutwik Joshi, Akhilesh Kumar Shakya, Wei Li   +4 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine.
Ana G. Lopes, Marianlie Navarro, Carmem Botelho, Maria J. Guimarães, Catarina Cerqueira, Joana Gomes, Celeste Brito   +6 more
doaj  

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation

Respirology, EarlyView.
ABSTRACT Asthma is a heterogeneous syndrome featuring variable pathophysiology, clinical presentation and treatment response. This review examines a comprehensive endotype‐phenotype framework for asthma assessment with an emphasis on characteristics beyond T2 inflammatory status alone.
Mario Fernando, Gregory G. King
wiley   +1 more source

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA, 2020
Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients
Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi   +8 more
doaj   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source